Search and Browse
Download
Enter Data
| Reaction Details | |||
|---|---|---|---|
 | Report a problem with these data | ||
| Target | Nociceptin receptor | ||
| Ligand | BDBM50100990 | ||
| Substrate/Competitor | n/a | ||
| Meas. Tech. | ChEMBL_1452449 (CHEMBL3362473) | ||
| Ki | 7.4±n/a nM | ||
| Citation |  Schunk, S; Linz, K; Frormann, S; Hinze, C; Oberbörsch, S; Sundermann, B; Zemolka, S; Englberger, W; Germann, T; Christoph, T; Kögel, BY; Schröder, W; Harlfinger, S; Saunders, D; Kless, A; Schick, H; Sonnenschein, H Discovery of Spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as Potent NOP and Opioid Receptor Agonists. ACS Med Chem Lett5:851-6 (2014) [PubMed] Article | ||
| More Info.: | Get all data from this article, Assay Method | ||
| Nociceptin receptor | |||
| Name: | Nociceptin receptor | ||
| Synonyms: | KOR-3 | Kappa-type 3 opioid receptor | Mu-type opioid receptor (Mu) | NOP | Nociceptin Receptor (ORL1 Receptor) | Nociceptin receptor (NOP) | Nociceptin receptor (ORL-1) | Nociceptin receptor (ORL1) | Nociceptin/Orphanin FQ, NOP receptor | OOR | OPIATE ORL-1 | OPRL1 | OPRL1 protein | OPRX_HUMAN | ORL1 | ORL1 receptor | Opioid receptor like-1 | Orphanin FQ receptor | Orphanin FQ receptor (ORL1) | P41146 | ||
| Type: | G Protein-Coupled Receptor (GPCR) | ||
| Mol. Mass.: | 40702.87 | ||
| Organism: | Homo sapiens (Human) | ||
| Description: | P41146 | ||
| Residue: | 370 | ||
| Sequence: |
| ||
| BDBM50100990 | |||
| n/a | |||
| Name | BDBM50100990 | ||
| Synonyms: | CHEMBL3325878 | ||
| Type | Small organic molecule | ||
| Emp. Form. | C22H32Cl2N2 | ||
| Mol. Mass. | 395.409 | ||
| SMILES | Cl.Cl.CN(C)[C@]1(CC[C@@H](CC1)NCCc1ccccc1)c1ccccc1 |r,wU:5.2,wD:8.9,(20.12,-18.98,;13.08,-21.67,;17.61,-17.09,;16.27,-16.32,;16.27,-14.78,;14.94,-17.09,;14.17,-18.42,;12.63,-18.43,;11.86,-17.1,;12.62,-15.77,;14.17,-15.76,;10.32,-17.1,;9.56,-18.44,;8.02,-18.45,;7.26,-19.79,;5.72,-19.79,;4.96,-21.13,;5.73,-22.46,;7.28,-22.45,;8.04,-21.11,;15.74,-18.41,;14.99,-19.76,;15.79,-21.08,;17.33,-21.05,;18.07,-19.69,;17.27,-18.37,)| | ||
| Structure | 
| ||